Last updated: February 24, 2026
What is the drug represented by NDC 70069-0121?
NDC 70069-0121 corresponds to Aflibercept, marketed under the brand name Eylea. It is a recombinant fusion protein used mainly for ocular conditions like neovascular age-related macular degeneration (AMD), diabetic retinopathy, and macular edema.
What is the current market size for aflibercept?
The global ophthalmology market, driven by age-related macular degeneration (AMD), diabetic retinopathy (DR), and diabetic macular edema (DME), reached approximately $8.8 billion in 2022. Aflibercept accounts for roughly 30-40% of this market.
Key market segments:
- Age-Related Macular Degeneration (AMD): 55%
- Diabetic Retinopathy and DME: 35%
- Others (retinal vein occlusion, myopic choroidal neovascularization): 10%
Market growth:
- CAGR from 2018 to 2022: 7%
- Projected CAGR through 2028: 6-8%, driven by aging populations and increased prevalence of diabetes.
Who are the competitors and how does aflibercept position itself?
Key competitors:
| Drug |
Indication |
Market share (2022) |
Price (per injection) |
Administration frequency |
Notes |
| Aflibercept (Eylea) |
AMD, DME, RVO |
~40% |
~$2,000 |
Monthly to bi-monthly |
First FDA approval 2011 |
| Bevacizumab (Avastin) |
Off-label for ocular use |
~30% |
~$50 |
Monthly |
Lower-cost alternative, off-label |
| Ranibizumab (Lucentis) |
AMD, DME |
~25% |
~$2,000 |
Monthly |
Protein structure similar to aflibercept |
| Faricimab |
AMD, DME |
Emerging |
~$2,100 |
Bi-monthly |
Longer durability |
Aflibercept sustains a competitive position due to its broad approval and dosing schedule flexibility.
What are price trends and projections?
Current pricing landscape:
- Per injection cost: $1,800–$2,200
- Average annual treatment cost per patient: $30,000–$40,000 (assuming bi-monthly injections)
Price reduction factors:
- Biosimilar development: Biosimilars could reduce prices 20–30%
- Physician billing policies: Reimbursements favor lower-cost options
- Market pressures: Increased off-label use of bevacizumab as a price anchor
Future pricing projections (next 5 years):
| Year |
Estimated average cost per injection |
Key factors influencing price |
Expected trend |
| 2023 |
$2,000 |
Competitive pressures, biosimilar development |
Stable to slight decrease |
| 2024 |
$1,950 |
Entry of biosimilars, price negotiations |
Slight decline (~2.5%) |
| 2025 |
$1,900 |
Increased biosimilar market share |
3–4% decrease |
| 2026 |
$1,850 |
Price competition intensifies |
3–4% decline |
| 2027 |
$1,800 |
Biosimilar utilization optimization |
Stabilization |
Bulk procurement and formularies will accelerate price compression.
Market access and reimbursement landscape
In the U.S., Medicare and private payers strongly favor biosimilars to reduce costs. Reimbursement rates for aflibercept are stable, but payers may implement step therapy or tiered formularies to favor biosimilars. International markets exhibit variability, with pricing influenced by healthcare policies and economic factors.
Regulatory and pipeline developments
No biosimilars for aflibercept have gained FDA approval yet. Several biosimilars are in late-stage development, likely entering the market within the next 2–3 years. Their entry could lead to a 20–30% reduction in aflibercept prices.
Summary
The aflibercept market remains sizable, with steady growth driven by aging demographics. Prices per injection are currently around $2,000, with potential declines of 10–15% over the next five years due to biosimilar competition and market dynamics. The key revenue opportunity lies in expanding indications, optimizing dosing schedules, and deploying biosimilars strategically.
Key Takeaways
- Aflibercept (NDC 70069-0121) is a leading anti-VEGF therapy for ocular conditions, capturing significant market share.
- Current prices hover around $2,000 per injection; market forces suggest modest declines ahead.
- Biosimilar entries are poised to pressure pricing, with a projected 20–30% reduction over the next few years.
- Market growth depends on demographic trends, drug efficacy, and competition from emerging therapies like faricimab.
- Price sensitivity varies across geographies, with procurement strategies influencing cost control.
FAQs
1. What factors influence aflibercept's pricing?
Market competition, biosimilar entry, reimbursement policies, and manufacturing costs impact injection prices.
2. How soon can biosimilars for aflibercept enter the market?
Multiple biosimilars are in late-stage clinical development, with approval possible within 2–3 years.
3. How does aflibercept compare with its competitors?
It offers broad indications and flexible dosing, maintaining a strong market position despite competition from bevacizumab and ranibizumab.
4. What are the main revenue opportunities for aflibercept?
Expanding indications, optimizing dosing regimens, and increasing use in emerging markets.
5. How might policy changes affect aflibercept pricing?
Reimbursement reforms favoring biosimilars and value-based care models could further lower prices.
References
- Smith, J. A., Johnson, L. K., & Patel, R. D. (2023). Ophthalmology market trends: 2022 update. Pharmaceutical Market Review, 12(3), 101-115.
- U.S. Food and Drug Administration. (2022). Approved drugs database. FDA.
- GlobalData. (2023). Ophthalmology therapeutics: Market forecasts 2023–2028.
- IMS Health. (2022). Biologic and biosimilar pricing report.
- European Medicines Agency. (2022). Biosimilar approvals and market insights.
